Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
In a recent ‘Viewpoint’ article, Dr. Fauci, Director of NIAID, mentioned that “industry has expanded the pipeline of new antibacterial drugs…with 14-agents currently in phase 3 clinical trials”.[1] Regarding the number of drugs in late development, his statement may be correct but many of these drugs are anything but new. Reviewing Continue reading The Antibiotic Pipeline: How “New” is New
An interesting report has just been published showing that Naloxegol is beneficial in OIC [i]. Naloxegol is a µ opioid receptor (MOR) antagonist which – by virtue of pegylation – acts peripherally and not centrally. Hence, the analgesic effects of opioid therapy are unaffected while the very bothersome side effect Continue reading Trial Pains Secondary to Placebo Effect?
US doctors seem to be very willing to start drugs earlier in disease, while their EU colleagues are slower and more conservative. Recent examples: the ever-wider indication for statins, the disproportionate uptake of drugs for attention-deficit / hyperactivity and opioids for pain relief. The new US HIV treatment guidelines are Continue reading HIV Therapy Guidance Recommendations Diverge, Show US Bias